| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT06911112 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an… |
Trial sites expanded: 10 -> 39 locations |
| 2026-08-01 | NCT07288320 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With… |
Trial sites expanded: 6 -> 9 locations |
| 2026-07-25 | NCT06966401 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive… |
Trial sites expanded: 98 -> 106 locations |
| 2026-07-25 | NCT07196501 A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in… |
Trial sites expanded: 45 -> 60 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive… | Schizophrenia | Recruiting |
| Phase 3 | |||
| NCT06786624 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in… | Major Depressive Disorder | Recruiting |
| NCT06963034 | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Schizophrenia | Recruiting |
| NCT07105098 | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Schizophrenia | Recruiting |
| NCT07114874 | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Schizophrenia | Recruiting |
| NCT07227818 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Schizophrenia | Recruiting |
| NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive… | Major Depressive Disorder | Recruiting |
| NCT07196501 | A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in… | Major Depressive Disorder | Recruiting |
| NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an… | Major Depressive Disorder | Recruiting |
| NCT06911112 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an… | Major Depressive Disorder | Recruiting |
| NCT04806451 | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants… | Congenital Adrenal Hyperplasia | Active, Not Recruiting |
| NCT04490915 | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal… | Congenital Adrenal Hyperplasia | Active, Not Recruiting |
| NCT06312189 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With… | Chorea, Huntington | Enrolling by Invitation |
| Phase 2 | |||
| NCT07365462 | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive… | Tardive Dyskinesia | Recruiting |
| NCT07288333 | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | Schizophrenia | Recruiting |
| NCT07288320 | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With… | Bipolar I Disorder | Recruiting |
| NCT07536269 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in… | Congenital Adrenal Hyperplasia | Not Yet Recruiting |
| NCT07187375 | Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital… | Congenital Adrenal Hyperplasia | Active, Not Recruiting |